Even for those who do not go to court or challenge each other’s iPS cell patents, but choose instead to go the licensure route, things are troubling. The organization in the driver’s seat is called iPS Academia Japan (AJ).

Sadly, iPS cell licensure is an expensive and nebulous undertaking.

On the AJ website the prices go to $50K per year and you’ll note that it says “From US$50K/year” for therapeutic uses.

The key word is “From”.

See image above from the AJ website. Ouch.

In other words, the sky’s the limit. Not so simple. Not so reassuring.

1 Comment

Of course you’re right in saying that “the current iPS cell IP arena and the associated costs are anything but simple or reassuring”…as I’ve written elsewhere (http://busaconsultingllc.com/scsi/organelles/cellular_dynamics_ipo.php), the iPSC IP landscape is nothing short of a minefield, to the extent that most industry leaders I talk to freely admit to not really knowing who owns what, which patents are really important, or how things will all shake out in the end. But, that said, license fees and royalties on the order of what iPS Academia Japan is charging really aren’t terribly onerous…at least in the commercial world. Actually, order-of-magnitude-wise, pretty much par for the course in the biotech tools industry. Of course, numbers like these are a different story for academic researchers…but then how many academics actually take out licenses? (That’s an actual question, not a rhetorical one…I got the heck out of academia before most academics could even spell ‘license’, much less worry about them, so I don’t really know).